Biogen (BSP:BIIB34) Scaled Net Operating Assets

: 0.62 (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biogen's operating assets for the quarter that ended in Mar. 2023 was R$101,865 Mil. Biogen's operating liabilities for the quarter that ended in Mar. 2023 was R$21,885 Mil. Biogen's Total Assets for the quarter that ended in Dec. 2022 was R$128,796 Mil. Therefore, Biogen's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2023 was 0.62.

Biogen Scaled Net Operating Assets Historical Data

The historical data trend for Biogen's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

0.77

0.64

0.73

0.66

0.59

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Scaled Net Operating Assets																0.56	0.63	0.60	0.61	0.62

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Scaled Net Operating Assets Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biogen's Scaled Net Operating Assets falls in comparison to its industry or sector. The grey bar indicates the Scaled Net Operating Assets's extreme value range as defined by GuruFocus.

Biogen Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biogen's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(103131.383	-	23875.487)	/	135023.744
=	0.59

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	128796.076	-	25664.693
=	103131.383

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	58568.563	-	34693.076	-	0
=	23875.487

Biogen's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2023 )
=	(Operating Assets (Q: Mar. 2023 )	-	Operating Liabilities (Q: Mar. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(101865.111	-	21884.975)	/	128796.076
=	0.62

where

	Operating Assets		(Q: Mar. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	128123.226	-	26258.115
=	101865.111

	Operating Liabilities		(Q: Mar. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	56312.258	-	34427.283	-	0
=	21884.975

Biogen Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Biogen's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines